Zobrazeno 1 - 10
of 149
pro vyhledávání: '"M, Oberhoff"'
Autor:
M. Oberhoff, W. A. Schöbel, Albrecht Elsässer, E. Kaiser, N. Petri, Wolfram Voelker, V. Schächinger, J. Petersen
Publikováno v:
Der Kardiologe. 11:44-47
Das Manual dient als Anlage zum Curriculum „Interventionelle Kardiologie“, das den Ausbildungsprozess fur die Zusatzqualifikation Interventionelle Kardiologie der DGK beschreibt. Die fur die Zusatzqualifikation erforderlichen Fertigkeiten konnen
Autor:
A, Blum, M, Oberhoff
Publikováno v:
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 67(11)
Autor:
A Blum, M Oberhoff
Publikováno v:
Der Hautarzt. 67:925-926
Autor:
M, Oberhoff, C, Herdeg, R, Al Ghobainy, S, Cetin, A, Küttner, B, Horch, A, Baumbach, K R, Karsch
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions. 53(4)
Paclitaxel is a new cancer chemotherapeutic agent that has been approved for clinical use in patients with a variety of different cancers. Paclitaxel inhibits cell proliferation by an action on microtubules. The aim of this study was to evaluate the
Autor:
H, Mahrholdt, K K, Haase, A, Baumbach, E, Dirr, M, Oberhoff, S, Schröder, A, Athanasiadis, K R, Karsch
Publikováno v:
Zeitschrift fur Kardiologie. 89(8)
The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA. This prospective study was performed to determine the efficacy of abciximab in a bail-out situati
Autor:
C, Herdeg, M, Oberhoff, D I, Siegel-Axel, A, Baumbach, A, Blattner, A, Küttner, S, Schröder, K R, Karsch
Publikováno v:
Zeitschrift fur Kardiologie. 89(5)
Paclitaxel, a potent anti-tumor agent, shifts the cytoskeleton equilibrium towards assembly of altered and extraordinarily stable microtubules. These cellular modifications lead to reduced proliferation, migration, and signal transduction. It is high
Publikováno v:
Medizinische Klinik (Munich, Germany : 1983). 95(3)
Quality control becomes increasingly important in interventional cardiology. Since in most health care systems, clinical treatment of patients who underwent percutaneous transluminal coronary angioplasty (PTCA) is left to general practitioners, impor
Publikováno v:
Seminars in interventional cardiology : SIIC. 3(3-4)
The implantation of stents can prevent vessels from post interventional elastic recoil and appears to limit adverse remodelling. In order to inhibit in-stent restenosis, an additional release of antiproliferative agents from the stent itself might le
Autor:
M, Oberhoff, A, Baumbach, T, Hermann, C, Diehl, R, Maier, A, Athanasiadis, C, Herdeg, A, Bohnet, K K, Haase, W, Voelker, R, Baildon, S, Veldhof, K R, Karsch
Publikováno v:
Catheterization and cardiovascular diagnosis. 44(3)
The purpose of this study was to assess safety and feasibility of intracoronary delivery of reviparin using a porous balloon following percutaneous transluminal coronary angioplasty. The 2.7 mm porous balloon used in this study had 35 holes arranged
Publikováno v:
Lasers in surgery and medicine. 21(1)
Bubble formation, pressure wave generation, and cavitations constitute major factors influencing the outcome of clinical Excimer laser angioplasty. Thus, the rationale of this study was to determine the extent of pressure waves occurring during excim